MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $612.09M
• Dividend Yield: N/A
• Average Volume (3M): 823.14K
• Price to Earnings (P/E): 20.6
• Beta (1Y): 0.69
• Revenue Growth: 14.77%
• EPS Growth: -58.90%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.10
• Shares Outstanding: 148,566,590
• 10 Day Avg. Volume: 804,762
• 30 Day Avg. Volume: 823,142
• PEG Ratio: 1.49
• Price to Book (P/B): 3.90
• Price to Sales (P/S): 2.39
• P/FCF Ratio: 13.71
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 1.12
• Enterprise Value/Gross Profit: 1.36
• Enterprise Value/Ebitda: 5.76
• 1Y Price Target: $9.50
• Price Target Upside: 130.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.11
• Revenue Forecast (FY): $347.51M

• Rating: 73 Outperform
• Price Target: $4.50 ▲(9.22% Upside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is driven primarily by strong financial performance (improving profitability, robust cash generation, and a very conservative balance sheet). The earnings call supports the fundamental trend with raised growth guidance and strong margins, but the technical picture is a headwind (below key longer-term moving averages with negative MACD), and valuation is only moderate with no dividend yield data.

Positive Factors

Conservative balance sheet

MiMedx’s minimal debt relative to a large equity base provides durable financial flexibility. A very low debt-to-equity position reduces refinancing and interest risks, supports continued clinical investment, potential M&A, and buffers the company through reimbursement or demand shocks over the next several quarters.

Strong cash generation

Sustained positive operating and free cash flow strengthens the company’s ability to self-fund trials, expand commercial efforts, and absorb regulatory or legal costs without relying on external capital. Reliable cash conversion supports durable reinvestment and liquidity for 2–6+ months horizons.

High margins and revenue momentum

Robust top-line growth alongside very high product-level gross margins (~82–88%) indicates strong product economics and clinician adoption. Diversified wound and surgical franchise growth increases revenue resilience and supports sustained profitability even amid pricing or site‑of‑care shifts.

Negative Factors

Medicare reimbursement uncertainty

Structural Medicare reimbursement changes expected in 2026 could materially alter pricing, coding, or site‑of‑care economics for placental‑derived products. Such regulatory shifts can reduce realized reimbursement, change hospital purchasing incentives, and require multi‑quarter commercial and clinical adjustments.

Ongoing legal and regulatory expenses

Sustained litigation and regulatory costs can drain cash, increase SG&A volatility, and distract management. Large or prolonged legal outcomes could reduce funds available for R&D, trials, or commercial expansion and impair margins over multiple quarters.

Historical profitability and cash volatility

Prior multi‑year negative cash flow and inconsistent operating margins show the business can revert to weak cash conversion under stress. Dependence on stable tissue sourcing, payor coverage, and clinician adoption means earnings and cash could fluctuate, reducing predictability over coming quarters.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

How the Company Makes Money

MiMedx primarily makes money by selling its placental tissue–derived biologic products to healthcare providers and facilities for use in wound management and surgical applications. Revenue is generated from product sales volume and pricing across its commercial portfolio, with demand influenced by clinician adoption, facility purchasing decisions, and payor reimbursement/coverage policies for specific indications and care settings. The company’s earnings are also affected by its ability to maintain reliable tissue sourcing and manufacturing, manage distribution to provider channels, and expand utilization through salesforce execution and clinical/real‑world evidence supporting product use. null

MiMedx Group Financial Statement Overview

Summary

Strong multi-year turnaround with rising revenue (2025 $418.6M vs. 2024 $348.9M), consistently high gross margins (~82–83%), solid profitability in 2024–2025 (~12% net margin), and improving operating/free cash flow (2025 OCF/FCF ~$74M). Balance sheet is a major strength with minimal debt (~$1.5M) versus equity (~$256.5M), though prior-year variability and some operating-profitability inconsistency remain watch items.

Income Statement

Profitability and growth have improved materially versus the 2020–2022 loss-making period. Revenue rose to $418.6M in 2025 (annual) from $348.9M in 2024, with very strong gross margins holding steady around ~82–83%. Net margins are solidly positive in 2024–2025 (~12%), though they are below the 2023 peak and operating profitability looks less consistent year-to-year (including an apparent anomaly in 2025 EBIT margin data). Overall, the income statement reflects a strong turnaround and resilient product-level economics, with some variability in below-the-line profitability.

Balance Sheet

The balance sheet strengthened significantly, highlighted by very low leverage in 2025 with total debt of ~$1.5M against stockholders’ equity of ~$256.5M (debt-to-equity ~0.01). Equity has expanded meaningfully from 2020–2022 levels, and returns on equity are strong in 2024–2025 (~19–22%), indicating improved earnings power on a larger capital base. A key watch item is that leverage was higher in earlier years (notably 2022), but the current balance sheet profile is conservatively positioned.

Cash Flow

Cash generation is strong and improving: operating cash flow increased to ~$74.0M in 2025 (annual) from ~$66.2M in 2024, with free cash flow also at ~$74.0M and positive growth. Cash flow quality is good, with operating cash flow exceeding net income in 2024–2025 (coverage ~1.15–1.45), supporting earnings durability. The main weakness is the historical volatility—cash flow was negative in 2020–2022 and coverage was weak in 2023—though the most recent two years show sustained positive conversion.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	418.63M	348.88M	321.48M	267.84M	242.02M
Gross Profit	345.62M	288.81M	266.84M	219.53M	202.39M
EBITDA	82.93M	65.35M	40.54M	-10.68M	-1.89M
Net Income	48.58M	42.42M	67.44M	-30.20M	-12.30M
Balance Sheet
Total Assets	342.65M	263.92M	239.05M	171.43M	187.93M
Cash, Cash Equivalents and Short-Term Investments	166.12M	104.42M	82.00M	65.95M	87.08M
Total Debt	22.53M	24.84M	48.10M	52.47M	53.29M
Total Liabilities	86.11M	70.81M	96.33M	96.92M	95.35M
Stockholders Equity	256.55M	193.11M	142.72M	74.51M	92.58M
Cash Flow
Free Cash Flow	72.97M	64.52M	24.79M	-19.41M	-5.20M
Operating Cash Flow	74.00M	66.20M	26.77M	-17.89M	-1.98M
Investing Cash Flow	-6.89M	-9.58M	-2.15M	-2.66M	-3.40M
Financing Cash Flow	-5.41M	-34.20M	-8.57M	-580.00K	-3.35M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Negative. The current price of 4.12 is below the 20-day moving average (MA) of 4.66, below the 50-day MA of 5.07, and below the 200-day MA of 6.41, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 20.15 is Positive, neither overbought nor oversold. The STOCH value of 6.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	73 Outperform	$612.09M	20.60	21.24%	―	14.77%	-58.90%
MAZE	68 Neutral	$2.31B	-9.86	-44.62%	―	―	―
ORIC	57 Neutral	$1.12B	-5.55	-38.79%	―	―	4.29%
PHAR	57 Neutral	$1.11B	440.65	0.83%	―	26.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATAI	48 Neutral	$1.27B	-4.71	-107.86%	―	―	―

MiMedx Group Corporate Events

MiMedx Group Updates Strategy in Wound Care Markets

On January 12, 2026, MiMedx Group updated its investor presentation, highlighting its strategy to drive growth in the sizeable wound care and surgical markets through innovation in placental-derived products, expanded clinical evidence, and disciplined capital allocation. The materials emphasize ongoing and planned clinical studies across multiple surgical specialties, the significant unmet medical and economic burden of chronic wounds and postoperative complications such as colorectal anastomotic leaks, and the company’s focus on leveraging its product portfolio and strong balance sheet to support continued revenue growth, profitability, and potential expansion via M&A, with implications for reinforcing its competitive position and value creation objectives for stakeholders.

The most recent analyst rating on (MDXG) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.